老年人常见肺部慢性纤维化疾病的诊疗进展

doi:10.3969/j.issn.1003-9198.2026.07.005

摘要/Abstract

摘要： 肺部慢性纤维化疾病(肺纤维化)从病因角度可分为特发性肺纤维化与继发性肺纤维化,且不同疾病亚型治疗原则存在差异。老年人作为肺纤维化的高发人群,其疾病管理面临多重独特挑战。本文系统综述老年人肺纤维化的发病机制、诊断评估、分型体系及个体化治疗进展,以期为改善老年患者临床结局提供参考。

关键词: 老年人, 肺纤维化, 间质性肺疾病, 发病机制, 个体化诊疗

Abstract: From an etiological perspective, chronic pulmonary fibrotic diseases (pulmonary fibrosis) are categorized into idiopathic pulmonary fibrosis and secondary pulmonary fibrosis, with treatment principles varying among different disease subtypes. Older adults, being a high-incidence population for pulmonary fibrosis, encounter multiple unique challenges in disease management. This article systematically reviews the pathogenesis, diagnostic evaluation, classification system, and progress in individualized treatment of pulmonary fibrosis in the elderly, aiming to provide references for improving the clinical outcomes of elderly patients.

Key words: aged, pulmonary fibrosis, interstitial lung disease, pathogenesis, personalized medicine

中图分类号:

R 563.13

邓纪旺, 郭莹. 老年人常见肺部慢性纤维化疾病的诊疗进展[J]. 实用老年医学, 2026, 40(7): 667-673.

DENG Jiwang, GUO Ying. Progress in the diagnosis and treatment of common chronic pulmonary fibrotic diseases in the elderly[J]. Practical Geriatrics, 2026, 40(7): 667-673.

参考文献

[1] GOLCHIN N, PATEL A, SCHEURING J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis[J].BMC Pulm Med, 2025, 25(1): 378.
[2] 李娜, 张彦萍. 结缔组织病相关间质性肺疾病诊治进展[J]. 临床荟萃, 2016, 31(5): 506-511.
[3] 杨育坤, 朱向情, 阮光萍, 等. 衰老与肺纤维化和慢性阻塞性肺疾病以及间充质干细胞的治疗作用[J]. 中国组织工程研究, 2019, 23(17): 2746-2752.
[4] 韦建茂, 高胜兰, 宋泽庆, 等. 细胞衰老在特发性肺纤维化中的作用及机制研究进展[J]. 海南医学, 2019, 30(5): 637-642.
[5] 钟长军. 氧化应激在特发性肺纤维化中的作用及其机制研究进展[J]. 安徽医学, 2012, 33(2): 245-247.
[6] 王诗尧. 特发性肺纤维化合并肺癌的临床诊治进展[J]. 现代医学与健康研究电子杂志, 2020, 4(5): 105-108.
[7] LEY B, RYERSON C J, VITTINGHOFF E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis[J]. Ann Intern Med, 2012, 156(10): 684-691.
[8] 中华医学会呼吸病学分会间质性肺疾病学组. 特发性肺纤维化诊断和治疗中国专家共识[J]. 中华结核和呼吸杂志, 2016, 39(6):427-432.
[9] 李莘, 吴琦. 经支气管冷冻肺活检在间质性肺疾病病理诊断中的应用[J]. 医学信息, 2020, 33(21): 32-34, 42.
[10] KING T E J R, BRADFORD W Z, CASTRO-BERNARDINI S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis[J]. N Engl J Med, 2014, 370(22): 2083-2092.
[11] 四川省医疗卫生与健康促进会呼吸与危重症医学专业委员会间质性肺疾病多学科诊治学组. 进展性肺纤维化表现的结缔组织病相关间质性肺疾病患者临床管理(四川省)专家共识[J]. 实用医院临床杂志, 2024, 21(2):29-38.
[12] RICHELDI L, DU BOIS R M, RAGHU G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis[J]. N Engl J Med, 2014, 370(22):2071-2082.
[13] 张琦. 尘肺病的康复治疗[J]. 当代矿工, 2025(11): 40-41.
[14] MAHER T M, ELISABETH B, LOUIS D, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis[J]. Respir Res, 2021, 22(1): 197.
[15] FLAHERTY K R, WELLS A U, COTTIN V, et al. Nintedanib in progressive fibrosing interstitial lung diseases[J]. N Engl J Med, 2019, 381(18): 1718-1727.
[16] 邓旭康, 刘水清, 熊波. 常规药物联合肺康复治疗对老年人间质性肺炎的有效性分析[J]. 深圳中西医结合杂志, 2020, 30(19): 101-102.